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BACKGROUND: Early onset inflammatory bowel disease (IBD) is generally 
aggressive, with a high probability of complications and need of surgery. Despite 
the introduction of highly effective biological drugs, treatment with azathioprine 
continues to be important even for early onset IBD; however, in these patients 
azathioprine response appears to be reduced. This study evaluated azathioprine 
doses, metabolite concentrations and their associations with patients’ age in 
children with IBD treated at 6 tertiary pediatric referral centers. 
METHODS: Azathioprine doses, metabolites and clinical effects were assessed 
after at least 3 months of therapy in 17 early onset (age<6 years, cases) and 51 
non-early onset (age>12 and <18 years, controls) IBD patients. Azathioprine 
dose was titrated on therapeutic efficacy (response and adverse effects). 
Azathioprine metabolites and thiopurine methyltransferase activity were 
determined by HPLC-UV methods. 
RESULTS: Frequency of patients in remission was similar among early onset 
and control group (respectively 82% and 84%, p-value=0.72). Early onset 
patients required higher doses of azathioprine (median 2.7 vs 2.0 mg/kg/day, p-
value=1.1x10-4). Different doses resulted in comparable azathioprine active 
thioguanine nucleotide (TGN) metabolite concentrations (median 263 vs 366 
pmol/8x108 erythrocytes, p-value=0.41) and methylmercaptopurine nucleotide 
concentrations (median 1455 vs 1532 pmol/8x108 erythrocytes, p-value=0.60). 
Lower TGN metabolites/azathioprine doses ratios were found in early onset 
patients (median 98 vs 184 pmol/8x108 erythrocytes/mg/kg/day, p-value=0.017). 
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Interestingly, early onset patients presented also higher TPMT activity (median 
476 vs 350nmol methyl-mercaptopurine/mg hemoglobin/h, p-value=0.046). 
CONCLUSIONS: This study demonstrated that early onset IBD patients present 
increased inactivating azathioprine metabolism, likely because of elevated 
activity of the enzyme thiopurine methyltransferase. 
 





Approximately 25% of inflammatory bowel diseases (IBDs), namely Crohn's 
disease (CD) and ulcerative colitis (UC), has an onset in childhood with an 
incidence, for patients aged <16 years, between 8 and 11 cases / 100.000 
inhabitants / year. The incidence of IBD in children has risen in the last decade, 
particularly for episodes of illness with onset early in life, defined as early onset 
(<6 years)(1, 2); incidence of early onset cases is ~10% of all pediatric cases(2). 
IBD in children is in general more aggressive, both in terms of disease extension 
and progression, with a high probability of complications and surgery; moreover, 
the disease proves much more aggressive the earlier the onset is(1). 
Pharmacological therapy of IBD is primarily aimed at inflammation treatment and 
control, through the use of drugs able to induce and maintain disease 
remission(3). Drugs currently available for induction and maintenance therapy of 
pediatric IBD, like glucocorticoids, azathioprine and biologics are less effective in 
early onset cases(4). For azathioprine, response to standard doses is reduced in 
early onset patients in comparison to those with onset at age older than 6 years: 
open studies showed that a higher dosage of azathioprine compared with 
conventional regimens should be used in patients with early onset IBD to achieve 
better response(5, 6). Azathioprine is a pro-drug and requires bioactivation to 
thioguanine nucleotides (TGN), through a complex pathway of enzymatic 
reactions, overlapping with the salvage pathway for nucleotides synthesis. 
Polymorphisms in genes for enzymes involved in the metabolism of azathioprine 
influence treatment’s efficacy and toxicity(7). Thiopurine methyltransferase 
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(TPMT) influences substantially azathioprine metabolism at several steps, 
thereby altering the formation of active TGNs(8). In patients with genetic variants 
leading to reduced activity of TPMT, the metabolic pathway of azathioprine is 
shifted in the direction of active TGNs(9). Polymorphisms in TPMT have been 
associated with an increased risk for azathioprine related adverse events in 
patients with IBD(10). The determination of azathioprine metabolites 
concentrations is considered to be an important tool for individualization of 
thiopurine therapy in order to verify patients’ compliance and adequate exposure 
to active metabolites(11). We therefore hypothesized that early onset IBD 
patients may present an altered azathioprine pharmacokinetics in comparison to 
non-early onset patients, leading to decrease sensitivity to azathioprine. The aim 
of this study was then to evaluate azathioprine doses, metabolite concentrations 
and their associations with patients’ age in early onset pediatric IBD patients in 
comparison to non-early onset pediatric IBD. 
 
 
MATERIALS AND METHODS 
 
Ethical considerations 
The study was approved by the local ethical committees and appropriate 
informed consent was obtained from all patients or their parents or tutors. 
 
Patients and eligibility criteria 
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In this study 68 patients with IBD were enrolled by the participating centers 
between October 2014 and September 2015. The inclusion criteria were age up 
to 6 years for cases and more than 12 years and less than 18 years for controls, 
previous diagnosis of IBD and treatment with azathioprine for at least 3 months 
and stable dose of azathioprine for at least 1 month. The exclusion criteria were 
patients with ileostomy or colostomy, disease needing surgery, fulminant 
ulcerative colitis or toxic megacolon, contemporary presence of other non 
controlled pathologies, concomitant therapy with anti-TNF biological agents 
(infliximab or adalimumab). Other co-treatments, such as aminosalycilates, 
glucocorticoids or enteral therapy were allowed. 
The patients enrolled were all the eligible consecutive cases taking azathioprine 
at the participating centers in the time-frame of the study. For each case, the first 
three consecutive controls enrolled in each center, matched on IBD diagnosis, 
were selected.  
 
Therapeutic protocol and sample collection 
This case control study was non-interventional and patients were treated 
according to standard care and enrolled cross-sectionally from patients treated in 
each participating hospital. Patients were treated with a dose escalating strategy 
to reduce the risk of adverse events starting however from a relatively high dose 
(median of 2 mg/kg). At subsequent follow-up visits, the dose was increased or 
reduced so as to obtain the optimal clinical response; the criteria used to 
increase or reduce the dose of azathioprine were the level of disease activity and 
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laboratory parameters used to monitor azathioprine toxicity (in particular 
leukocytes, erythrocytes and platelets counts, hemoglobin concentration, MCV, 
liver enzymes ALT, AST and -GGT and amylase levels).  
Blood samples, collected for measuring azathioprine metabolites, TPMT activity 
and for genotyping, were taken at the first clinic visit occurring after at least three 
months of therapy and one month on stable azathioprine dose. Timing of sample 
collection was independent from clinical response status and results of 
pharmacokinetic analysis did not affect clinicians in their therapeutic choices. 
 
 
Definition of clinical response 
Clinical response was assessed, using Pediatric Crohn’s Disease Activity Index 
(PCDAI)(12) and Pediatric Ulcerative Colitis Activity Index (PUCAI)(13) 
respectively for CD and UC patients, at the time of blood sample collection for 
the metabolites’ measurement. Disease was considered inactive if the disease 
activity index was lower than 10 at the time of sample collection. Successful 
therapy or inactive disease were not among the inclusion criteria. 
 
Measurement of azathioprine metabolites 
Azathioprine metabolites (TGN and methylmercaptopurine nucleotides, MMPN) 
were measured at the Department of Life Sciences, University of Trieste in 
patients’ erythrocytes using an HPLC assay by Dervieux et al.(14). Blood 
samples were centrifuged for collection of erythrocytes, as previously described; 
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erythrocytes were stored at -80°C until analysis, which was performed within a 
month from collection. Metabolites concentration is expressed as pmol / 8x108 
erythrocytes. The ratio between TGN and the dose of azathioprine was 
calculated considering for each individual measurement the dose the patients 
was taking the day the blood sample for the metabolites assessment was 
collected. 
 
Measurement of TPMT activity 
TPMT activity was measured for all patients at the Department of Life Sciences, 
University of Trieste by HPLC assay based on in vitro conversion of 
mercaptopurine to methyl-mercaptopurine, using S-adenosyl-methionine as the 
methyl donor(15). TPMT activity is expressed as nmol of methyl-mercaptopurine 
produced by lysates of patients’ erythrocytes, containing 1 mg of hemoglobin, 
during 1 h of incubation at 37 °C in the presence of mercaptopurine. TPMT 
activity was measured concurrently to azathioprine metabolites, if the amount of 
patients’ erythrocytes was sufficient. 
 
Genotypes 
Genomic DNA was extracted from peripheral blood samples using a commercial 
kit (SIGMA, Milan, Italy), in order to characterize the most relevant genetic 
polymorphisms in the candidate gene TPMT (rs1800462, rs1800460, rs1142345), 





Statistical analysis was performed using the software R (version 3.2.4). 
The association between pharmacological phenotypes of interest (i.e, therapeutic 
response, dose of azathioprine, TGN metabolites concentrations, MMPN 
metabolites concentrations, ratio TGN/dose, TPMT activity, concomitant 
therapies) and the considered covariates (i.e, demographic variables including 
age-group classification, IBD type, TPMT genotypes) was evaluated in a 
univariate analysis by using generalized linear models of appropriate family 
(gaussian/ANOVA for continuous and binomial/logistic regression for categorical 
variables). In these univariate analyses, the dependent variable was the 
pharmacological phenotype of interest and the independent variable the 
demographic, clinical or pharmacogenetic covariate. 
Multivariate analysis was done to test the independence of the significant effects 
identified in univariate analyses on the phenotypes considered; for this 
multivariate analysis generalized linear models of the appropriate family were 
used combining covariates significant in the univariate analysis as the 
independent variables. For all parametric analysis (i.e, linear models used in the 
univariate analysis and the multivariate analysis), normality of the phenotype was 
tested by the Shapiro test and log10 or Box-cox transformation was applied if 
needed, in order to adjust the normality of the distribution.  
 
RESULTS 
Patients enrolled and samples collected 
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The present study recruited 17 early onset patients with inflammatory bowel 
disease, matched to 51 later onset pediatric IBD patients, considered as controls. 
Demographic and clinical characteristics are reported in Table 1. From October 
2014 to September 2015 peripheral blood samples have been collected to 
measure azathioprine metabolites. Among these, 27 were obtained during 
treatment with azathioprine alone and 41 during treatment with azathioprine and 
other medications and in particular: 26 with an aminosalicylate, 6 with a 
glucocorticoid, 6 with an aminosalicylate and a glucocorticoid, 2 with an 
aminosalicylate and an antibiotic and 1 with enteral nutrition; no significant 
difference could be observed for co-treatments between cases and controls. In 
particular, frequency of patients taking aminosalycilates with azathioprine was 
similar between cases and controls (respectively 41.2% vs 52.9%, p-value 
logistic regression = 0.40). At the time of the evaluation, none of the patients was 
on allopurinol, furosemide or any other medication that could interfere with 
thiopurine metabolism.  
 
Genotyping 
TPMT genotyping is available for all cases and 48 controls; in 3 control patients, 
genotyping could not be performed due to technical reasons. All polymorphisms 
considered were respecting Hardy-Weinberg equilibrium and their distribution is 
comparable to what has been reported in the literature for patients of Caucasian 
ethnicity. Frequency of TPMT variant genotypes was similar among cases and 
controls: in particular, 1 early onset patient (5.9%) and 2 non-early onset patients 
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(4.2%) presented the variant heterozygous genotype of rs1142345 (A719G) (p-
value logistic regression = 0.77). Among these, the early onset patient and one 
non-early onset patient presented also the rs1800460 (G460A) variant in 
heterozygous form. No patient presented the rs1800462 (G238C) variant. 
Therefore, in terms of variant alleles, 2 patients (1 case and 1 control) were 
heterozygous for TPMT*3A, while 1 control was heterozygous for TPMT*3C. All 
other 62 patients with available DNA for genotyping were considered 
homozygous for the TPMT*1 allele. 
 
Clinical efficacy in patients with early onset IBD in comparison to non-early 
onset patients 
Clinical response was determined: frequency of patients in remission was not 
different among early onset and control group (respectively 82% and 84%, odds 
ratio early onset vs non-early onset = 0.76, 95% C.I. = 0.18 – 3.89, p-value 
logistic regression = 0.72). 
 
Azathioprine doses and metabolites in patients with early onset IBD in 
comparison to non-early onset patients 
Early onset patients required higher doses of azathioprine (median 2.7 vs 2.0 
mg/kg/day, p-value ANOVA = 1.1x10-4, Figure 1). This difference was present 
even considering separately patients with CD and UC (see Figure, 
Supplementary Digital Content 1). Different doses resulted in comparable 
azathioprine active TGN metabolites concentrations (median 263 vs 366 pmol / 
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8x108 erythrocytes, p-value ANOVA = 0.41, Figure 2) and MMPN concentrations 
(median 1455 vs 1532 pmol / 8x108 erythrocytes, p-value ANOVA = 0.60, Figure 
3). Lower TGN metabolites / azathioprine dose ratios were found in early onset 
patients (median 98 vs 184 pmol / 8x108 erythrocytes/mg/kg/day, p-value 
ANOVA = 0.017, Figure 4). Treatment duration was not different between cases 
and controls (median 553, interquartile range (IQR) 250-670 vs 402, IQR 176-
771.5 days, p-value ANOVA = 0.77). For all covariates besides azathioprine dose, 
considering CD and UC patients separately, the trends were similar to those 
described in the grouped pediatric IBD patients, even if no significant difference 
can be calculated, likely because of the reduction in population size in the 
separated groups (data not shown). 
 
TPMT activity in patients with early onset IBD in comparison to non-early 
onset IBD patients 
TPMT activity could be measured in a subset of patients for which sufficient 
blood sample was available after the quantification of thiopurine metabolites, in 
particular 9 early onset and 27 non-early onset IBD patients. This population was 
representative of the whole group since no demographic variable was different 
between this subgroup of patients and the whole study population in terms of the 
demographic, clinical and pharmacological variables. Interestingly, early onset 
patients presented higher activity of TPMT (Figure 5, median 476 vs 350 nmol of 




Additional univariate analysis on demographic, clinical and 
pharmacogenetic covariates and azathioprine pharmacokinetics 
Type of IBD showed a fully significant effect on the median TGN or TGN/dose 
ratio in our population (respectively median 284 pmol / 8x108 erythrocytes in 
Crohn’s patients vs 372 pmol / 8x108 erythrocytes in UC patients for TGN, p-
value ANOVA = 0.015, and 140 pmol / 8x108 erythrocytes/mg/kg/day in Crohn’s 
patients vs 185 pmol / 8x108 erythrocytes/mg/kg/day in UC patients for TGN/dose 
ratio, p-value ANOVA = 0.021); therefore an increased concentration of active 
thiopurine metabolites in UC patients compared to CD was evident, as previously 
reported(9). Gender did not show any significant association with azathioprine 
doses, metabolites or TPMT activity in this population. TPMT variant genotype 
was significantly associated in a univariate analysis with a reduction in MMPN 
concentration (1610 pmol / 8x108 erythrocytes in TPMT wild-type vs 261 pmol / 
8x108 erythrocytes in TPMT variants, p-value ANOVA = 0.017) and an increase 
in TGN/dose ratio (159 pmol / 8x108 erythrocytes/mg/kg/day in TPMT wild-type 
vs 291 pmol / 8x108 erythrocytes/mg/kg/day in TPMT variants, p-value ANOVA = 
0.0055) as well established.  
 
Multivariate analysis evaluating independence of the effects of the 
genotypes on azathioprine metabolites concentrations or dose 
For azathioprine dose, TGN concentrations, MMPN concentrations and TPMT 
activity, no multivariate analysis was done, since only one covariate had a fully 
significant effect in a univariate analysis (see above). For TGN/dose ratio, the 
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multivariate generalized linear model showed that early onset IBD, UC type of 
IBD and variant TPMT genotype are independent determinants of increased 
concentration of TGN metabolites per unit of azathioprine administered. Detailed 
results of this multivariate analyses are reported in Table 2. 
 
DISCUSSION 
In this study, performed on children with IBD treated at 6 Italian tertiary referral 
centers, we demonstrate for the first time that early onset IBD patients (age <6 
years old) have profound differences in azathioprine pharmacokinetics in 
comparison to non-early onset patients (age between 12 and 18 years old): in 
particular, the ratio of active TGN metabolites per unit of daily azathioprine dose 
is significantly reduced in early onset patients. This could explain the much 
higher doses required by early onset patients, in order to achieve similar efficacy. 
Indeed, the larger doses administered resulted in similar concentration of active 
metabolites in early onset and older child with IBD. Interestingly, early onset IBD 
was associated with increased activity of TPMT, the main enzyme involved in 
azathioprine biotransformation, further supporting the hypothesis that early onset 
IBD patients have increased inactivation of thiopurines and therefore may be less 
sensitive to the drug than non-early onset patients. 
Azathioprine is frequently used in IBD and is important to maintain remission; 
however, a significant proportion of patients does not respond to therapy or 
develops important adverse events(16, 17). The causes for this inter-individual 
variability in response to azathioprine are not completely understood; however, a 
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consistent amount of evidence relates variability in azathioprine response to 
inter-individual differences in the metabolism of the medication, that are due, at 
least in part, to genetic polymorphisms of relevant enzymes(9), such as TPMT 
and NUDT15, which is particularly important in Asian patients (18). 
It has been previously described that the activity of one of the most relevant 
enzymes involved in azathioprine biotransformation, TPMT, is elevated in 
newborns, in comparison to children(19), and in younger children in comparison 
to older ones and adults(20). The observation of higher TPMT activity in younger 
children has not been supported by all published studies(21), however most of 
the studies not describing a relevant age-effect on TPMT were focused on adult 
patients and spanning all age groups, with the addition of potential 
confounders(22). Many studies in children on azathioprine pharmacokinetics, 
especially those in IBD patients, are still underpowered(23), therefore this study 
is the first one to clearly present the differences in azathioprine pharmacokinetics 
of early onset IBD patients. However studies performed in larger populations of 
patients with acute lymphoblastic leukemia also support lack of efficacy of 
thiopurines in younger patients, due to reduced concentration of active TGN 
metabolites and potentially increased TPMT activity(24). Indeed, a recent large 
study on TPMT activity in children with leukemia confirmed that younger age is 
associated with increased TPMT activity(25). 
Our current study is non interventional, therefore the potential clinical application 
of its findings are limited; however, the practice of administering high doses of 
thiopurines in early onset IBD, to improve therapeutic efficacy, is common and 
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should be explored by properly designed randomized controlled trials in order to 
define strategies to further improve therapy with thiopurines in this age group.  
One may assume that an integrated approach including non-genetic (e.g. 
developmental) and genetic factors may improve our understanding of 
azathioprine response(26). On these bases, there is a strong clinical 
recommendation to elucidate the impact of higher azathioprine dosage (3.5 
mg/kg/day) in pediatric patients with early onset IBD by a randomized 
prospective "dose finding" trial to develop an age-specific formulation for a 
chronic highly debilitating disease, especially for patients’ with early onset. Liquid 
formulations for younger children may also be preferable and could be 
considered(27).  
In this study, we do not provide evidence on the molecular mechanism by which 
TPMT is increased in early onset IBD. Epigenetic mechanisms, in particular 
methylation of gene promoters, have been proposed in ontogenesis of enzymes 
responsible for drug biotransformation(28), such as cytochromes(29). Innovative 
studies could be performed to test whether similar age-dependent epigenetic 
mechanisms occur also for TPMT promoter methylation(30). Moreover, besides 
increased TPMT activity, also other enzymes involved in azathioprine 
metabolism, such as glutathione transferases, could be reduced in early onset 
patients and increased during development, affecting azathioprine 
pharmacokinetics and efficacy, and could be evaluated in further studies(9, 17). 
In addition to differences in biotransformation, other pharmacokinetic factors, 
influenced by age, may contribute to the requirement for higher azathioprine 
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doses described by our study, such as changes in absorption and 
bioavailability(5, 31). TPMT activity might have been affected by concomitant 
mesalazine treatment (32); however, frequency of patients in therapy with 
mesalazine was not significantly different between cases and controls. 
Azathioprine therapy itself could have influenced TPMT activity: since cases 
were on higher doses of azathioprine, TPMT activity might be raised because of 
that (33); however, induction of TPMT activity by thiopurine treatment in patients 
with IBD is controversial (34). Finally, our early onset population did not include 
patients with very-early onset disease (less than 1 year old): studies focusing in 
this important although rare patients’ population could be considered (2). One 
strength of this study is that all laboratory tests for azathioprine metabolites, 
TPMT activity, and TPMT genotype were done at the same centralized laboratory 
(35). 
In conclusion, this study demonstrates that early onset IBD patients present an 
increased inactivating azathioprine metabolism, possibly because of elevated 
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Table 1: demographic and clinical characteristic of patients enrolled 
  
All patients 




(age < 6 
years) 
(n = 17) 
non-early 
onset 
(age >12 - 
<18 years) 
(n = 51) 
p-value* 
Age (years) at time of sample collection** 
14.7, 







Female (%) 28 (43) 8 (47) 21 (41) 
0.67 
Male (%) 39 (57) 9 (53) 30 (59) 
Type of IBD 
Crohn’s disease (%)  16 (23) 4 (23) 12 (23) 
1 
Ulcerative colitis (%) 52 (76) 13 (76) 39 (76) 








Table 2: multivariate analysis for covariates with a significant effect in the univariate analysis 
Azathioprine related pharmacological 
phenotype (dependent variable) 
Independent variable in 
multivariate generalized linear 
model 
Comparison Effect* p-value** 
Ratio TGN/dose 
Age of IBD onset Early vs Later 1.1 0.013 





ulcerative colitis vs 
Crohn’s disease 
0.89 0.047 
*: The effect size represents the increase (positive value) or decrease (negative value) in the value of the dependent 





Figure 1: the boxplots show stable azathioprine doses (mg/kg/day) in patients 
with early onset IBD (age < 6 years old) or non-early onset IBD (age > 12 years 
and < 18 years old) obtained after at least three months of therapy; empty and 
solid points display azathioprine dose values for patients with wild-type and 
variant TPMT respectively; p-value is from ANOVA. 
 
Figure 2: the boxplots show TGN concentrations (pmol/8x108 erythrocytes) in 
patients with early onset IBD (age < 6 years old) or non-early onset IBD (age > 
12 years and < 18 years old); empty and solid points display TGN concentration 
values for patients with wild-type and variant TPMT respectively; p-value is from 
ANOVA. TGN concentrations values were log-transformed to adjust normality. 
 
Figure 3: the boxplots show MMPN concentrations (pmol/8x108 erythrocytes) in 
patients with early onset IBD (age < 6 years old) or non-early onset IBD (age > 
12 years and < 18 years old); empty and solid points display MMPN 
concentration values for patients with wild-type and variant TPMT respectively; p-
value is from ANOVA. MMPN concentration values were transformed according 
to Box-Cox method (final exponent 0.1) to adjust normality. 
 
Figure 4: the boxplots show the ratio between TGN concentrations and 
azathioprine doses (pmol/8x108 erythrocytes mg/kg/day) in patients with early 
onset IBD (age < 6 years old) or non-early onset IBD (age > 12 years and < 18 
24 
 
years old); empty and solid points display MMPN concentration values for 
patients with wild-type and variant TPMT respectively; p-value is from ANOVA. 
TGN/azathioprine dose ratios were transformed according to Box-Cox method 
(final exponent 0.4) to adjust normality. 
 
Figure 5: the boxplots show TPMT activity values (nmol of methylmercaptopurine 
produced by patients’ erythrocytes lysates containing 1 mg of hemoglobin during 
1 h of incubation at 37 °C in the presence of mercaptopurine) in patients with 
early onset IBD (age < 6 years old) or non-early onset IBD (age > 12 years and < 
18 years old); empty and solid points display TPMT activity values for patients 
with wild-type and variant TPMT respectively; p-value is from ANOVA. 
25 
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n= 9 n= 27
p−value = 0.046
